265 related articles for article (PubMed ID: 16778093)
41. Review of clinic trials: agents targeting c-Met.
Abidoye O; Murukurthy N; Salgia R
Rev Recent Clin Trials; 2007 May; 2(2):143-7. PubMed ID: 18473999
[TBL] [Abstract][Full Text] [Related]
42. Therapeutic targeting of the receptor tyrosine kinase Met.
Sattler M; Ma PC; Salgia R
Cancer Treat Res; 2004; 119():121-38. PubMed ID: 15164876
[No Abstract] [Full Text] [Related]
43. Drug development of MET inhibitors: targeting oncogene addiction and expedience.
Comoglio PM; Giordano S; Trusolino L
Nat Rev Drug Discov; 2008 Jun; 7(6):504-16. PubMed ID: 18511928
[TBL] [Abstract][Full Text] [Related]
44. ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity.
Munshi N; Jeay S; Li Y; Chen CR; France DS; Ashwell MA; Hill J; Moussa MM; Leggett DS; Li CJ
Mol Cancer Ther; 2010 Jun; 9(6):1544-53. PubMed ID: 20484018
[TBL] [Abstract][Full Text] [Related]
45. MET signalling: principles and functions in development, organ regeneration and cancer.
Trusolino L; Bertotti A; Comoglio PM
Nat Rev Mol Cell Biol; 2010 Dec; 11(12):834-48. PubMed ID: 21102609
[TBL] [Abstract][Full Text] [Related]
46. Met gene copy number predicts the prognosis for completely resected non-small cell lung cancer.
Okuda K; Sasaki H; Yukiue H; Yano M; Fujii Y
Cancer Sci; 2008 Nov; 99(11):2280-5. PubMed ID: 19037978
[TBL] [Abstract][Full Text] [Related]
47. Targeting the c-MET signaling pathway for cancer therapy.
Liu X; Yao W; Newton RC; Scherle PA
Expert Opin Investig Drugs; 2008 Jul; 17(7):997-1011. PubMed ID: 18549337
[TBL] [Abstract][Full Text] [Related]
48. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib.
Bean J; Brennan C; Shih JY; Riely G; Viale A; Wang L; Chitale D; Motoi N; Szoke J; Broderick S; Balak M; Chang WC; Yu CJ; Gazdar A; Pass H; Rusch V; Gerald W; Huang SF; Yang PC; Miller V; Ladanyi M; Yang CH; Pao W
Proc Natl Acad Sci U S A; 2007 Dec; 104(52):20932-7. PubMed ID: 18093943
[TBL] [Abstract][Full Text] [Related]
49. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.
Engelman JA; Zejnullahu K; Mitsudomi T; Song Y; Hyland C; Park JO; Lindeman N; Gale CM; Zhao X; Christensen J; Kosaka T; Holmes AJ; Rogers AM; Cappuzzo F; Mok T; Lee C; Johnson BE; Cantley LC; Jänne PA
Science; 2007 May; 316(5827):1039-43. PubMed ID: 17463250
[TBL] [Abstract][Full Text] [Related]
50. LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models.
Yan SB; Peek VL; Ajamie R; Buchanan SG; Graff JR; Heidler SA; Hui YH; Huss KL; Konicek BW; Manro JR; Shih C; Stewart JA; Stewart TR; Stout SL; Uhlik MT; Um SL; Wang Y; Wu W; Yan L; Yang WJ; Zhong B; Walgren RA
Invest New Drugs; 2013 Aug; 31(4):833-44. PubMed ID: 23275061
[TBL] [Abstract][Full Text] [Related]
51. Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clones.
Marchetti A; Milella M; Felicioni L; Cappuzzo F; Irtelli L; Del Grammastro M; Sciarrotta M; Malatesta S; Nuzzo C; Finocchiaro G; Perrucci B; Carlone D; Gelibter AJ; Ceribelli A; Mezzetti A; Iacobelli S; Cognetti F; Buttitta F
Neoplasia; 2009 Oct; 11(10):1084-92. PubMed ID: 19794967
[TBL] [Abstract][Full Text] [Related]
52. Extracellular Matrix Influencing HGF/c-MET Signaling Pathway: Impact on Cancer Progression.
Noriega-Guerra H; Freitas VM
Int J Mol Sci; 2018 Oct; 19(11):. PubMed ID: 30352967
[TBL] [Abstract][Full Text] [Related]
53. HER3/Akt/mTOR pathway is a key therapeutic target for the reduction of triple‑negative breast cancer metastasis via the inhibition of CXCR4 expression.
Takeda T; Tsubaki M; Genno S; Tokunaga K; Tanaka R; Nishida S
Int J Mol Med; 2023 Sep; 52(3):. PubMed ID: 37477145
[TBL] [Abstract][Full Text] [Related]
54. Single Inhibitors versus Dual Inhibitors: Role of HDAC in Cancer.
Roy R; Ria T; RoyMahaPatra D; Sk UH
ACS Omega; 2023 May; 8(19):16532-16544. PubMed ID: 37214715
[TBL] [Abstract][Full Text] [Related]
55. The Receptor Tyrosine Kinase c-Met Promotes Lipid Accumulation in 3T3-L1 Adipocytes.
Park YK; Jang BC
Int J Mol Sci; 2023 Apr; 24(9):. PubMed ID: 37175792
[TBL] [Abstract][Full Text] [Related]
56. Effect of Food on the Pharmacokinetics and Safety of a Novel c-Met Inhibitor SCC244: A Randomized Phase I Study in Healthy Subjects.
Wu J; Xu H; Li H; Ma L; Chen J; Yuan F; Sheng L; Liu C; Chen W; Li X
Drug Des Devel Ther; 2023; 17():761-769. PubMed ID: 36925997
[TBL] [Abstract][Full Text] [Related]
57. Vascular Niche Facilitates Acquired Drug Resistance to c-Met Inhibitor in Originally Sensitive Osteosarcoma Cells.
Tang W; Zhang Y; Zhang H; Zhang Y
Cancers (Basel); 2022 Dec; 14(24):. PubMed ID: 36551686
[TBL] [Abstract][Full Text] [Related]
58. A miniaturized screening platform to identify novel regulators of extracellular matrix alignment.
Jones CE; Sharick JT; Sizemore ST; Cukierman E; Strohecker AM; Leight JL
Cancer Res Commun; 2022 Nov; 2(11):1471-1486. PubMed ID: 36530465
[TBL] [Abstract][Full Text] [Related]
59. MET gene alterations predict poor survival following chemotherapy in patients with advanced cancer.
Ko J; Jung J; Kim ST; Hong JY; Park S; Park JO; Park YS; Lim HY; Ahn S; Kim KM; Kang WK; Lee J
Pathol Oncol Res; 2022; 28():1610697. PubMed ID: 36483096
[No Abstract] [Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
